Osteoarticular Tumor Characterization by Advanced Imaging

Central Hospital, Nancy, France1,090 enrolled

Overview

The purpose is to compare and evaluate multiple functional imaging methods (perfusion, diffusion, spectroscopy) for initial benign/malignant characterization of osteoarticular tumors and to determine which method or which association of methods could improve non invasive tissue characterization. Secondary purposes are: * to determine a possible correlation between some parameters and the histological grade (FNCLCC) * to suggest a coherent diagnostic imaging approach for osteoarticular tumors. The ancillary study will enroll patients needing radiological tumor follow-up. The purpose is to identify tools for evaluation of tumor activity and therapeutic response before modification of morpho-volumetric data.

Patients refered for the initial evaluation of suspected osteoarticular masses will be included in this study after signing an informed consent. Histologic analysis will be used as a gold standard. The following imaging techniques will be evaluated: * contrast enhanced ultrasonography * Low dose CT perfusion * Magnetic resonance perfusion * Diffusion weighted imaging * Magnetic resonance proton spectroscopy

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

1,090

Conditions

Bone Tumor Soft Tissue Tumor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients examined for initial assessment of bone or peripheral soft-tissue primitive tumor * patients with normal awareness level * patients having signed informed consent Exclusion Criteria: * pregnant women * persons deprived of liberty * persons under legal protection or unable to give informed consent * persons in life-threatening emergency * allergy to Sonovue, iodinated contrast media or gadolinium chelates * risk of pregnancy * breastfeeding women * acute coronary syndrome or unstable ischemic cardiopathy (ban on injection of contrast agent for CT scan) * renal failure (ban on injection of contrast agent for MRI and CT scan) * contraindication to MRI

Outcomes

Primary Outcomes

Contrast enhancement in echography: yes or no

Time frame: baseline

Contrast enhancement curve (absent, slow or fast) in echography

Time frame: baseline

Maximal intensity of enhancement peak in echography

Time frame: baseline

Mean transit time of enhancement in echography

Time frame: baseline

Gradient of contrast enhancement curve in echography

Time frame: baseline

Vascularization (dynamic analysis) in CT scanner

* 0: absent * 1: low (\< 20UH) * 2: \> 20 UH without new blood vessels * 3: \> 20 UH and/or with new blood vessels

Time frame: baseline

Contrast enhancement curve (absent, slow or fast) in CT scanner

Time frame: baseline

Maximal intensity of enhancement peak in CT scanner

Time frame: baseline

Mean transit time of enhancement in CT scanner

Time frame: baseline

Gradient of contrast enhancement curve in CT scanner

Time frame: baseline

Contrast enhancement curve (absent, slow or fast) in MRI

Time frame: baseline

Maximal intensity of enhancement peak in MRI

Time frame: baseline

Mean transit time of enhancement in MRI

Time frame: baseline

Gradient of contrast enhancement curve in MRI

Time frame: baseline

Choline peak in magnetic resonance spectroscopy

Choline presence was defined as a clear metabolite peak at 3.2 ppm

Time frame: baseline

Apparent diffusion coefficient (ADC) in MR diffusion weighted imaging

ADC value in mm2/s

Time frame: baseline

Area under the perfusion curve in MRI

Time frame: baseline

Perfusion curve gradient in MRI

Time frame: baseline

Perfusion time-to-peak in MRI

Time frame: baseline

Osteoarticular Tumor Characterization by Advanced Imaging

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts